Eric Mosbrooker - 06 Aug 2025 Form 4 Insider Report for Avidity Biosciences, Inc. (RNA)

Role
Chief Commercial Officer
Signature
/s/ John B. Moriarty, Jr., J.D., Attorney-in-Fact
Issuer symbol
RNA
Transactions as of
06 Aug 2025
Net transactions value
-$4,635,279
Form type
4
Filing time
08 Aug 2025, 17:45:20 UTC
Previous filing
08 Jan 2025
Next filing
05 Sep 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Mosbrooker Eric Chief Commercial Officer C/O AVIDITY BIOSCIENCES, INC., 10578 SCIENCE CENTER DRIVE, SUITE 125, SAN DIEGO /s/ John B. Moriarty, Jr., J.D., Attorney-in-Fact 08 Aug 2025 0001715283

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RNA Common Stock Options Exercise $1,128,417 +124,687 +204% $9.05 185,807 06 Aug 2025 Direct F1
transaction RNA Common Stock Sale $5,494,033 -124,687 -67% $44.06 61,120 06 Aug 2025 Direct F1, F2
transaction RNA Common Stock Sale $269,663 -6,120 -10% $44.06 55,000 06 Aug 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RNA Stock Option (Right to Buy) Options Exercise $0 -124,687 -40% $0.000000 190,313 06 Aug 2025 Common Stock 124,687 $9.05 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 11, 2024.
F2 This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.54 to $45.44. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 1/48th of the total number of shares subject to the option shall vest on each monthly anniversary of January 1, 2024 (the "Vesting Commencement Date"), subject to the Reporting Person's continuous service to the Issuer on each such vesting date, so that the options shall be fully vested on the fourth anniversary of the Vesting Commencement Date.